Sglt2 Inhibitor
HF after diabetes diagnosis raises 5-year mortality risk, lowers life span
Patients who developed HF at any time after their diabetes diagnosis had the greatest relative and absolute risk for death at 5 years compared with those with diabetes who had other CV or renal diagnoses, researchers reported.
Simplified management protocol can prevent, treat DKA in COVID-19
Alternative, patient-tailored strategies are needed to treat diabetic ketoacidosis in the setting of COVID-19 to better balance intensive insulin therapy with minimizing clinician exposure and preserving personal protective equipment.
VERTIS-CV: Ertugliflozin CV neutral, HF benefit seen in type 2 diabetes
Adults with type 2 diabetes and established atherosclerotic cardiovascular disease were no more likely to experience a CV event during 3.5 years of follow-up with the SGLT2 inhibitor ertugliflozin compared with placebo, study data show.
DAPA-HF: Dapagliflozin reduces new-onset diabetes among adults with heart failure
Adults with heart failure assigned the SGLT2 inhibitor dapagliflozin had a 32% lower risk for new-onset type 2 diabetes over 18 months of follow-up vs. placebo, according to a planned analysis of DAPA-HF trial data.
Aggressive management in stage 3 CKD preserves kidney function in diabetes
Adults with type 2 diabetes and a low estimated glomerular filtration rate must be more aggressively managed with tailored treatment options to preserve kidney function and reduce morbidity and mortality risk.
Realize the potential of adjunctive therapy in the treatment of type 1 diabetes
One approach to improve care and clinical outcomes for people with type 1 diabetes involves the use of adjunctive therapies along with insulin to improve glucose control or enable reductions in insulin doses.
FDA OKs dapagliflozin for heart failure regardless of diabetes status, plus more top stories in cardiology
FDA approves dapagliflozin for HFrEF regardless of diabetes status
AstraZeneca announced the FDA has approved its SGLT2 inhibitor dapagliflozin to reduce risk for CV death and HF hospitalization in patients with HF with reduced ejection fraction with and without type 2 diabetes.
FDA approves dapagliflozin for HFrEF regardless of diabetes status
AstraZeneca announced the FDA has approved its SGLT2 inhibitor dapagliflozin to reduce risk for CV death and HF hospitalization in patients with HF with reduced ejection fraction with and without type 2 diabetes.
FDA: Suspend SGLT2 inhibitors before surgery
The FDA on Tuesday approved safety labeling changes for all SGLT2 inhibitors, recommending temporary discontinuation of the medications before any scheduled surgery to avoid potential risk for diabetic ketoacidosis, according to an agency press release.